Fig. 7: OVs encoding antigens can be used as platforms for personalized vaccines. | Nature Communications

Fig. 7: OVs encoding antigens can be used as platforms for personalized vaccines.

From: Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Fig. 7

a Treatment schedule used in this study. b IFNγ ELISPOT analysis of splenocytes from mice primed with Ad-Ova  ± DCT peptide and boosted with MRB-Ova  ± DCT peptide (from left to right; n = 2, 5 and 3). The statistical analyses refer to the comparison between the corresponding ex-vivo “No restim” and “restim” conditions. NS: p > 0.05, ***: p < 0.001 (unpaired multiple two-tailed t-test). c Tumor growth and survival analyses of mice bearing established SC B16F10-Ova tumors treated with Ad-Ova and MRB-Ova together or not with B16Mut20, B16Mut30, B16Mut44 and B16Mut48 (n = 10). Data are presented as mean values ± SEM. *: p < 0.05, ***: p < 0.001 (unpaired multiple two-tailed t-test). Kaplan–Meier survival analysis: ***: p < 0.001 (Mantel–Cox test, two-sided). Source data are provided as a Source Data file. Exact p values can be found in the Source Data.

Back to article page